AstraZeneca gets further approval for Tagrisso in Japan
Alecensa has aced Pfizer’s rival in head-to-head trial
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
But AZ is anxiously waiting for results of MYSTIC trial